Artemis Therapeutics Inc.
ATMS · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -9,298.22 | 0.73 | -0.00 |
| FCF Yield | 0.00% | 0.00% | -0.14% | -0.89% |
| EV / EBITDA | -364,661.46 | 0.00 | -259.17 | -14.12 |
| Quality | ||||
| ROIC | 0.00% | 0.00% | 39.26% | 79.77% |
| Gross Margin | 94.89% | 93.69% | 83.24% | 75.00% |
| Cash Conversion Ratio | 0.39 | 0.08 | 0.13 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | 875,369.14% | 849,380.65% | 776,450.07% | 665,805.83% |
| Free Cash Flow Growth | 0.00% | 0.00% | -63.72% | 8.47% |
| Safety | ||||
| Net Debt / EBITDA | -2.07 | 0.00 | -1.49 | -0.61 |
| Interest Coverage | 0.00 | 0.00 | 17.60 | -41.17 |
| Efficiency | ||||
| Inventory Turnover | 0.09 | 0.00 | 0.83 | 0.62 |
| Cash Conversion Cycle | -5,595.91 | 0.00 | -1,850.07 | -1,594.40 |